Program Description:
The majority of patients with metastatic colorectal cancer (mCRC) are characterized by microsatellite stable or mismatch repair proficient tumors, which can be associated with limited responsiveness to immunotherapy and poorer long-term outcomes. Following progression on standard first- and second-line regimens, patients without actionable mutations enter a complex third-line treatment landscape. In these instances, evidence-based options such as regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib offer modest but meaningful survival benefits. These therapies, many of which are orally administered, introduce adherence challenges, nuanced dosing schedules, and toxicity management considerations that are often compounded by residual toxicities from prior therapies. Despite guideline recommendations supporting their use, real-world data suggest underutilization and retreatment with earlier lines, highlighting gaps in sequencing. This webinar is designed for oncology pharmacists across community, Veterans Affairs, and ambulatory care settings and will provide practical guidance on therapy selection, pharmacogenomic considerations, and proactive toxicity management, including laboratory monitoring, early identification of adverse effects, and patient-specific counseling strategies for patients with mCRC. Emphasis will also be placed on emerging therapies and evolving evidence, interdisciplinary coordination, and the expanding role of pharmacist-led oral oncology services in optimizing adherence, safety, and outcomes in this increasingly complex later-line mCRC setting.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: June 30, 2026
Expiration date: August 30, 2026
Time to complete activity: 1.25 hours
Learner level: Foundational
Fee: Free
Educational
Objectives:
At the completion of this activity, participants will be able to:
- Apply current clinical evidence and molecular profiling to guide selection of third-line therapies in mismatch repair proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without actionable mutations
- Identify common and serious adverse effects associated with third-line therapies for pMMR/MSS mCRC and their clinical presentation in patients
- Develop effective patient counseling strategies to improve adherence, safe administration, and clinical benefit of third-line therapies in pMMR/MSS mCRC